Aura Biosciences (AURA) Income from Continuing Operations (2020 - 2026)
Aura Biosciences' (AURA) quarterly Income from Continuing Operations came in at 33685000.0 in Q1 2026, down 22.57% YoY from 43501943.28 in Q1 2025, and down 142.28% on a QoQ basis from 79674000.0 in Q4 2025.
Aura Biosciences (AURA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Income from Continuing Operations data on file, last reported at 33685000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 22.57% year-over-year to 33685000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7160000.0 (up 92.52% YoY) and the FY2025 annual result came in at 958000.0, up 98.91% from the prior year.
- Income from Continuing Operations retreated to 33685000.0 in Q1 2026, from 79674000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 79674000.0 in Q4 2025 to a low of 74303000.0 in Q1 2022.
- A 5-year average of 23043529.41 and a median of 22131000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 1135.3% — and 2025, when it jumped 396.12%.
- Tracing AURA's Income from Continuing Operations over 5 years: stood at 18381000.0 in 2022, then slipped by 20.4% to 22131000.0 in 2023, then dropped by 21.58% to 26906000.0 in 2024, then surged by 396.12% to 79674000.0 in 2025, then slumped by 142.28% to 33685000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 33685000.0 (Q1 2026), 79674000.0 (Q4 2025), and 26130000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | -45.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.64 Mn |
| Mar 31, 2026 | -33.69 Mn |
| Dec 31, 2025 | 79.67 Mn |
| Sep 30, 2025 | -26.13 Mn |
| Jun 30, 2025 | -27.02 Mn |
| Mar 31, 2025 | -27.48 Mn |
| Dec 31, 2024 | -26.91 Mn |
| Sep 30, 2024 | -21.04 Mn |
| Jun 30, 2024 | -20.34 Mn |
| Mar 31, 2024 | -19.71 Mn |
| Dec 31, 2023 | -22.13 Mn |
| Sep 30, 2023 | -18.51 Mn |
| Jun 30, 2023 | -18.30 Mn |
| Mar 31, 2023 | -17.47 Mn |
| Dec 31, 2022 | -18.38 Mn |
| Sep 30, 2022 | -59.05 Mn |
| Jun 30, 2022 | -40.96 Mn |
| Mar 31, 2022 | -74.30 Mn |
| Dec 31, 2021 | -11.78 Mn |
| Sep 30, 2021 | -22.95 Mn |